OA11756A - Core tablet for controlled release of gliclazide after oral administration. - Google Patents

Core tablet for controlled release of gliclazide after oral administration. Download PDF

Info

Publication number
OA11756A
OA11756A OA1200100197A OA1200100197A OA11756A OA 11756 A OA11756 A OA 11756A OA 1200100197 A OA1200100197 A OA 1200100197A OA 1200100197 A OA1200100197 A OA 1200100197A OA 11756 A OA11756 A OA 11756A
Authority
OA
OAPI
Prior art keywords
giiclazide
gliclazide
tablet according
matrix tablet
polymer compound
Prior art date
Application number
OA1200100197A
Other languages
English (en)
Inventor
Bruno Huet De Barochez
Patrick Wuthrich
Louis Martin
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9541429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11756(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adir filed Critical Adir
Publication of OA11756A publication Critical patent/OA11756A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA1200100197A 1999-02-01 1999-10-15 Core tablet for controlled release of gliclazide after oral administration. OA11756A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9901082A FR2788981B1 (fr) 1999-02-01 1999-02-01 Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale

Publications (1)

Publication Number Publication Date
OA11756A true OA11756A (en) 2005-07-19

Family

ID=9541429

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100197A OA11756A (en) 1999-02-01 1999-10-15 Core tablet for controlled release of gliclazide after oral administration.

Country Status (37)

Country Link
US (1) US6733782B1 (hr)
EP (1) EP1148871B1 (hr)
JP (2) JP4716465B2 (hr)
KR (1) KR100491600B1 (hr)
CN (1) CN1160061C (hr)
AP (1) AP1243A (hr)
AT (1) ATE296621T1 (hr)
AU (1) AU764516B2 (hr)
BR (1) BR9917012A (hr)
CA (1) CA2273420C (hr)
CZ (1) CZ298196B6 (hr)
DE (1) DE69925639T2 (hr)
DK (1) DK1148871T3 (hr)
EA (1) EA002625B1 (hr)
EE (1) EE05024B1 (hr)
ES (1) ES2241323T3 (hr)
FR (1) FR2788981B1 (hr)
GE (1) GEP20053501B (hr)
HK (1) HK1043049A1 (hr)
HR (1) HRP20010632B1 (hr)
HU (1) HU225693B1 (hr)
ID (1) ID30225A (hr)
IL (2) IL144246A0 (hr)
ME (1) ME00436B (hr)
NO (1) NO329951B1 (hr)
NZ (1) NZ512878A (hr)
OA (1) OA11756A (hr)
PL (1) PL194505B1 (hr)
PT (1) PT1148871E (hr)
RS (1) RS50121B (hr)
SA (1) SA00210446B1 (hr)
SK (1) SK285209B6 (hr)
TR (1) TR200102002T2 (hr)
UA (1) UA68414C2 (hr)
WO (1) WO2000018373A1 (hr)
YU (1) YU53101A (hr)
ZA (1) ZA200106305B (hr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
SE0200539D0 (sv) * 2002-02-25 2002-02-25 Metcon Medicin Ab Granulation process and starch granulate
CN100391459C (zh) * 2003-05-26 2008-06-04 沈阳药科大学 甲磺酸多沙唑嗪缓释制剂
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
CA2563325C (en) * 2004-04-29 2010-06-22 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
CN100413491C (zh) * 2004-06-14 2008-08-27 北京德众万全药物技术开发有限公司 一种难溶性药物的控释制剂
WO2006061697A1 (en) * 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
US9029427B2 (en) * 2005-11-11 2015-05-12 Asahi Kasei Chemicals Corporation Controlled release solid preparation
US20080286343A1 (en) * 2007-05-16 2008-11-20 Dzenana Cengic Solid form
TR200704897A1 (tr) * 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Uzatılmış salım sağlayan gliklazid formülasyonları@
TR200708938A2 (tr) * 2007-12-26 2008-11-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salım sağlayan gliklazid tablet
ITFI20080016A1 (it) * 2008-02-05 2009-08-06 Valpharma Sa Formulazioni farmaceutiche orali contenenti gliclazide.
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
WO2009140279A2 (en) * 2008-05-12 2009-11-19 Concert Pharmaceuticals, Inc. Sulfonyl urea compounds
EP2181705A1 (en) 2008-10-31 2010-05-05 Disphar International B.V. Sustained-release formulation of gliclazide
CA2753057C (en) * 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
AR081935A1 (es) 2010-06-16 2012-10-31 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada
TR201107482A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
EP2468268B1 (en) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Combination composition of vildagliptin and gliclazide
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
IN2014DN07897A (hr) * 2012-02-24 2015-04-24 Ranbaxy Lab Ltd
WO2014128116A1 (en) * 2013-02-19 2014-08-28 Sanovel Ilac Sanayi Ve Ticaret A.S. A production process for gliclazide formulations
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
ITMI20132065A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
LT3170005T (lt) 2014-07-18 2019-07-10 Sanofi Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas
WO2016042568A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of gliclazide
CN111329841B (zh) * 2020-03-04 2021-11-19 山东鲁抗医药集团赛特有限责任公司 格列齐特缓释片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1449404A (en) * 1973-03-30 1976-09-15 Science Union & Cie N-arylsulphonyl urea derivatives
US4056623A (en) * 1975-03-05 1977-11-01 Science Union Et Cie, Societe Francaise De Recherche Medicale Methods of treating animals suffering from hyperlipidemia using certain N-phenyl sulphonyl-N'-(3-azabicycloalkyl) ureas
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
DE4336159A1 (de) * 1993-10-22 1995-04-27 Kurt Heinz Prof Dr Bauer Hochwirksame, den Wirkstoff schnell oder kontrolliert freisetzende Zubereitungsformen von Sulfonylharnstoffen und Verfahren zu deren Herstellung
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.

Also Published As

Publication number Publication date
CA2273420C (fr) 2002-07-09
BR9917012A (pt) 2002-04-16
JP4716465B2 (ja) 2011-07-06
HUP0105365A3 (en) 2002-11-28
EP1148871A1 (fr) 2001-10-31
TR200102002T2 (tr) 2002-01-21
HRP20010632B1 (en) 2006-02-28
AU764516B2 (en) 2003-08-21
SK10952001A3 (sk) 2001-12-03
CN1342068A (zh) 2002-03-27
NO20013757D0 (no) 2001-07-31
PT1148871E (pt) 2005-08-31
PL356707A1 (en) 2004-06-28
NZ512878A (en) 2002-05-31
EE200100398A (et) 2002-10-15
EP1148871B1 (fr) 2005-06-01
WO2000018373A1 (fr) 2000-04-06
UA68414C2 (en) 2004-08-16
KR20010093307A (ko) 2001-10-27
CA2273420A1 (fr) 2000-08-01
US6733782B1 (en) 2004-05-11
HK1043049A1 (en) 2002-09-06
CZ20012661A3 (cs) 2001-11-14
ID30225A (id) 2001-11-15
RS50121B (sr) 2009-03-25
EA200100827A1 (ru) 2002-02-28
JP2002525310A (ja) 2002-08-13
GEP20053501B (en) 2005-05-10
NO20013757L (no) 2001-08-09
AP2001002212A0 (en) 2001-09-30
EA002625B1 (ru) 2002-06-27
ME00436B (me) 2011-10-10
DE69925639D1 (de) 2005-07-07
ZA200106305B (en) 2002-07-31
IL144246A (en) 2006-12-10
CZ298196B6 (cs) 2007-07-18
DE69925639T2 (de) 2006-04-27
HRP20010632A2 (en) 2005-02-28
KR100491600B1 (ko) 2005-05-27
DK1148871T3 (da) 2005-09-19
JP2008179649A (ja) 2008-08-07
FR2788981B1 (fr) 2002-05-17
ATE296621T1 (de) 2005-06-15
NO329951B1 (no) 2011-01-31
SA00210446B1 (ar) 2006-10-11
HU225693B1 (en) 2007-06-28
SK285209B6 (sk) 2006-08-03
IL144246A0 (en) 2002-05-23
AP1243A (en) 2004-02-02
FR2788981A1 (fr) 2000-08-04
EE05024B1 (et) 2008-06-16
PL194505B1 (pl) 2007-06-29
YU53101A (sh) 2004-05-12
ES2241323T3 (es) 2005-10-16
AU6098299A (en) 2000-04-17
CN1160061C (zh) 2004-08-04
HUP0105365A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
OA11756A (en) Core tablet for controlled release of gliclazide after oral administration.
US5334392A (en) Matrix tablet permitting the sustained release of indapamide after oral administration
JP2007314578A (ja) 経口投与後のトリメタジジンの持続性放出を可能とするマトリックス錠
US5888542A (en) Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route
WO2020148219A1 (en) A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby
US20060182803A1 (en) Oral sustained-release pharmaceutical composition of indapamide, production and use thereof
EP3911305B1 (en) A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby
MXPA01007378A (en) Core tablet for controlled release of gliclazide after oral administration
US20080138412A1 (en) Sustained release alfuzosin hydrochl formulation and method for their production
KR20060130006A (ko) 경구 서방성 정제
Narla et al. Formulation and evaluation of sustained release metoprolol succinate matrix tablets by direct compression process by using Kollidon SR
US20090264495A1 (en) Oral sustained-release pharmaceutical composition of indapamide, production and use thereof
SI20625A (sl) Matrična tableta, ki omogoča upočasnjeno sproščanje gliklazida po oralnem dajanju
NZ243201A (en) Sustained release tablets containing indapamide.
LT4932B (lt) Štampuota tabletė, duodanti prolonguotą gliklazido išsiskyrimą, vartojant ją peroraliniu būdu